English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The severe type of idiopathic sudden sensor-ineural hearing loss (ISSHL) was treated with recombinant interferon alpha-2a (IFN-α) (3MU/day for 10 days) without steroids. Complete recovery was observed in nine out of eleven patients with severe ISSHL, and the hearing of the remaining two patients recovered ≥30dB.Ototoxicity, including sensorineural hearing loss has been reported to be induced by IFN. Our results with IFN in ISSHL suggest that, although IFN can be ototoxic at high doses, low dose IFN may be effective in the treatment of ISSHL caused by inner ear damage.Thus, IFN may actually be an effective substitute for steroids in ISSHL therapy.

IFN for Treatment of Severe Idiopathic Sudden Sensorineural Hearing Loss. IFN Therapy without Steroids.